DYAI · Dyadic International Inc · Financials
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, our management has concluded that there is substantial doubt about our ability to continue as a going concern, which depends upon our obtaining necessary financing to meet our obligations and repay our liabilities arising from normal business operations as they come due.”View the 10-Q filed Aug 12, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $3.8M | $3.09M | $3.5M | $2.9M | $2.93M | $2.4M | $1.6M | $1.68M | $1.3M | $758.42K | |
| $3.18M | $2.32M | $1.19M | $1.98M | $2.12M | $1.94M | $1.42M | $1.46M | $1.03M | $680.2K | |
| $617.62K | $770.49K | $2.3M | $922.96K | $807.11K | $459.39K | $176.99K | $221.38K | $268.17K | $78.22K | |
| — | 24.93% | 65.82% | 31.84% | 27.54% | 19.11% | 11.05% | 13.17% | 20.7% | 10.31% | |
| $6.17M | $5.76M | $6.13M | $5.82M | $6.42M | $6.7M | $6.08M | $5.52M | $4.52M | $5.03M | |
| $11.22M | $10.28M | $9.4M | $11.13M | $13.1M | $17.13M | $11.63M | $10.96M | $8.89M | $7.89M | |
| -$7.42M | -$7.19M | -$5.9M | -$8.23M | -$10.17M | -$14.73M | -$10.03M | -$9.28M | -$7.59M | -$7.13M | |
| — | -232.75% | -168.82% | -283.9% | -346.92% | -612.67% | -625.85% | -552.18% | -586.09% | -939.7% | |
| $243.4K | $284.09K | $456.99K | — | — | — | — | — | — | — | |
| -$203.67K | -$171.81K | $91.66K | $1.43M | $430.42K | $1.66M | $731.71K | — | $894.53K | $4.92M | |
| — | — | $60.98K | $1.02M | — | — | — | — | — | — | |
| — | — | — | — | — | $0 | $31.32K | $10.31K | -$1.01M | -$66.69K | |
| -$7.62M | -$7.36M | -$5.81M | -$6.8M | -$9.74M | -$13.07M | -$9.33M | -$8.31M | -$5.69M | -$2.14M | |
| — | -238.31% | -166.19% | -234.42% | -332.23% | -543.73% | -582.13% | -494.21% | -439.36% | -281.61% | |
| USD/shares | -$0.21 | -$0.23 | -$0.20 | -$0.24 | -$0.34 | -$0.47 | — | — | — | — |
| USD/shares | -$0.21 | -$0.23 | -$0.20 | — | — | — | — | — | — | — |
| shares | — | — | — | 28.8M | 28.36M | 27.84M | 27.47M | 27M | 27.67M | 28.92M |
| shares | — | 32.62M | 29.32M | — | — | 27.84M | 27.47M | 27M | 27.67M | 28.92M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2019: $8.53M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 222 similar-size Biotechnology companies (of 516 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Grant | $1,858,034 | — | — | — | — |
| Research and Development | $967,311 | $1,605,220 | $2,545,865 | $2,683,244 | $2,403,831 |
| License | $265,000 | $890,169 | $352,941 | $247,059 | $0 |